Bryn Mawr Capital Management LLC Lowers Stock Position in Johnson & Johnson (NYSE:JNJ)

Bryn Mawr Capital Management LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 2.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 129,038 shares of the company’s stock after selling 3,316 shares during the period. Johnson & Johnson comprises about 1.0% of Bryn Mawr Capital Management LLC’s portfolio, making the stock its 18th largest position. Bryn Mawr Capital Management LLC’s holdings in Johnson & Johnson were worth $18,661,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Nelson Capital Management LLC raised its holdings in shares of Johnson & Johnson by 10.9% in the fourth quarter. Nelson Capital Management LLC now owns 6,124 shares of the company’s stock valued at $886,000 after purchasing an additional 601 shares during the last quarter. Shayne & Jacobs LLC raised its holdings in shares of Johnson & Johnson by 7.8% in the fourth quarter. Shayne & Jacobs LLC now owns 2,094 shares of the company’s stock valued at $303,000 after purchasing an additional 152 shares during the last quarter. National Pension Service increased its holdings in Johnson & Johnson by 0.4% during the fourth quarter. National Pension Service now owns 4,586,490 shares of the company’s stock worth $663,298,000 after buying an additional 18,836 shares during the last quarter. Fjell Capital LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth about $898,000. Finally, DMKC Advisory Services LLC purchased a new stake in Johnson & Johnson during the fourth quarter worth about $1,581,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on JNJ. Barclays raised their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Wells Fargo & Company decreased their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Morgan Stanley decreased their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Finally, Guggenheim lifted their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Price Performance

JNJ stock opened at $165.23 on Friday. The firm has a 50 day moving average of $150.90 and a 200-day moving average of $156.06. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The firm has a market capitalization of $397.81 billion, a P/E ratio of 24.85, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the business earned $2.29 earnings per share. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.00%. Johnson & Johnson’s payout ratio is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.